Deze pagina is automatisch vertaald en de nauwkeurigheid van de vertaling kan niet worden gegarandeerd. Raadpleeg de Engelse versie voor een brontekst.

Een studie van CDPATH™ om de ziekte van Crohn te helpen beheersen en behandelen (COMPASS-CD)

5 oktober 2026 bijgewerkt door: Takeda

Een fase 4-onderzoek ter evaluatie van het gebruik in de praktijk van CDPATH™, een risicovoorspellingsinstrument voor de ziekte van Crohn

CDPATH™ is a tool to help predict the potential for developing Crohn's disease related complications in certain adult participants within 3 years. The main aim of the study is to explore the use of CDPATH™ to describe a participant's risk profile and to have discussions with their doctor about the potential path of their Crohn's disease. The number of visits will be decided by the study clinic according to their standard practice.

Studie Overzicht

Toestand

Voltooid

Conditie

Interventie / Behandeling

Gedetailleerde beschrijving

The tool being tested in this study is called CDPATH™. CDPATH™ is being used to provide a graphical representation of an individual participant's risk of developing a CD-related complication within three years, leveraging known participant risk factors based on clinical, serologic and genetic variables to help people categorize risk who have CD. This study will gather data on the use of the tool in real-world settings to inform practical use of CDPATH™.

The study will enroll approximately 200 patients. Participants and health care providers (HCPs) will be surveyed to understand their satisfaction with the CDPATH™ process and with their treatment choice.

This multi-center trial will be conducted in the United States. The overall time to participate in this study is 36 months. Participants will make multiple visits to the HCP's clinic, and data will be collected approximately every six months up to 3 years, based on the timing of routine follow-up appointments for assessment.

Studietype

Ingrijpend

Inschrijving (Werkelijk)

241

Fase

  • Fase 4

Contacten en locaties

In dit gedeelte vindt u de contactgegevens van degenen die het onderzoek uitvoeren en informatie over waar dit onderzoek wordt uitgevoerd.

Studie Locaties

    • Arizona
      • Phoenix, Arizona, Verenigde Staten, 85032
        • Arizona Arthritis & Rheumatology Research, PLLC
    • California
      • Loma Linda, California, Verenigde Staten, 92357
        • VA Loma Linda Healthcare System
      • Murrieta, California, Verenigde Staten, 92563
        • United Medical Doctors
      • Newport Beach, California, Verenigde Staten, 92663
        • University of Southern California Medical Center
      • Orange, California, Verenigde Staten, 92868
        • University of California at Irvine Medical Center
      • Orange, California, Verenigde Staten, 92868
        • Clinnova Research Solutions
    • Colorado
      • Aurora, Colorado, Verenigde Staten, 80014
        • Kaiser Permanate of Colorado
    • Connecticut
      • Hamden, Connecticut, Verenigde Staten, 06518
        • Medical Research Center of Connecticut, LLC
    • Florida
      • Clearwater, Florida, Verenigde Staten, 33762
        • West Central Gastroenterology d/b/a Gastro Florida
      • Pensacola, Florida, Verenigde Staten, 32503
        • Gastroenterology Associates of Pensacola, PA
    • Idaho
      • Idaho Falls, Idaho, Verenigde Staten, 83404
        • Grand Teton Research Group, PLL
    • Illinois
      • Arlington Heights, Illinois, Verenigde Staten, 60005
        • GI Alliance
      • Gurnee, Illinois, Verenigde Staten, 60031
        • GI Alliance
      • Northbrook, Illinois, Verenigde Staten, 60062
        • Comprehensive Gastrointestinal Health
      • Rockford, Illinois, Verenigde Staten, 61107
        • Rockford Gastroenterology Associates, Ltd.
    • Indiana
      • Indianapolis, Indiana, Verenigde Staten, 46202
        • Indiana University
    • Iowa
      • Clive, Iowa, Verenigde Staten, 50325
        • Iowa Digestive Disease Center
      • Iowa City, Iowa, Verenigde Staten, 52242-1009
        • University of Iowa Hospitals & Clinics
    • Kansas
      • Kansas City, Kansas, Verenigde Staten, 66160
        • University of Kansas Medical Center Research Institute, Inc.
    • Louisiana
      • Baton Rouge, Louisiana, Verenigde Staten, 70809
        • GI Alliance - Baton Rouge
      • Shreveport, Louisiana, Verenigde Staten, 71105
        • Louisiana Research Center, LLC
    • Maryland
      • Columbia, Maryland, Verenigde Staten, 21045
        • Gastro Center of Maryland
    • Massachusetts
      • Burlington, Massachusetts, Verenigde Staten, 01805
        • Lahey Clinic Inc. - PARENT ACCOUNT
      • Worcester, Massachusetts, Verenigde Staten, 01655
        • UMASS Memorial Medical Center
    • New Mexico
      • Albuquerque, New Mexico, Verenigde Staten, 87131-0001
        • University of New Mexico
    • New York
      • New York, New York, Verenigde Staten, 10075-1850
        • Lenox Hill Hospital
    • Ohio
      • Beavercreek, Ohio, Verenigde Staten, 45431
        • Clinical Inquest Center Ltd
      • Dayton, Ohio, Verenigde Staten, 45415
        • Dayton Gastroenterology, Inc
    • Oregon
      • Portland, Oregon, Verenigde Staten, 97220-9442
        • The Oregon Clinic, P.C.
    • Pennsylvania
      • Camp Hill, Pennsylvania, Verenigde Staten, 17011
        • Susquehanna Research Group, LLC
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15213
        • University of Pittsburgh Medical Center Health System
      • Pittsburgh, Pennsylvania, Verenigde Staten, 15212
        • Allegheny Center for Digestive Health
      • Uniontown, Pennsylvania, Verenigde Staten, 15401
        • Frontier Clinical Research, LLC
    • South Carolina
      • Summerville, South Carolina, Verenigde Staten, 29486
        • Palmetto Primary Care Physician Division of Gastroenterology
    • South Dakota
      • Rapid City, South Dakota, Verenigde Staten, 57701
        • Rapid City Medical Center, LLC
    • Tennessee
      • Nashville, Tennessee, Verenigde Staten, 37204
        • Vanderbilt University Medical Center
    • Texas
      • Austin, Texas, Verenigde Staten, 78712
        • The University of Texas at Austin
      • Houston, Texas, Verenigde Staten, 77030
        • Baylor College of Medicine
      • Southlake, Texas, Verenigde Staten, 76092
        • GI Alliance - Southlake
    • Utah
      • Ogden, Utah, Verenigde Staten, 84403
        • Care Access Research Berkley
      • Salt Lake City, Utah, Verenigde Staten, 84132
        • University of Utah
    • Virginia
      • Fairfax, Virginia, Verenigde Staten, 22031
        • GCGA Physicians LLC
      • Lynchburg, Virginia, Verenigde Staten, 24502
        • Gastroenterology Associates
    • Washington
      • Bellevue, Washington, Verenigde Staten, 98405
        • GI Alliance

Deelname Criteria

Onderzoekers zoeken naar mensen die aan een bepaalde beschrijving voldoen, de zogenaamde geschiktheidscriteria. Enkele voorbeelden van deze criteria zijn iemands algemene gezondheidstoestand of eerdere behandelingen.

Geschiktheidscriteria

Leeftijden die in aanmerking komen voor studie

18 jaar en ouder (Volwassen, Oudere volwassene)

Accepteert gezonde vrijwilligers

Nee

Geslachten die in aanmerking komen voor studie

Allemaal

Beschrijving

Inclusion Criteria:

  1. Has an initial diagnosis of CD established within five years prior to screening by clinical and endoscopic evidence and corroborated by a histopathology report (if available).
  2. Has agreed to use the CDPATH™ tool.
  3. Has reliable access to the internet and is willing to answer electronic patient-reported outcomes (ePROs) throughout the study.

Exclusion Criteria:

  1. Has had known complications from CD including but not limited to: bowel stricture, CD-related intra-abdominal abscess, internal penetrating disease (known fistula other than perianal fistula), non-perianal surgery, bowel resection, or stricturoplasty. A perianal fistula or abscess without other signs of penetrating disease is allowed.
  2. Has had any non-CD-related abdominal surgery.
  3. Has received investigational biologic or nonbiologic agents for the treatment of CD in an investigational protocol. Approved biologic or nonbiologic agents for CD are allowed.
  4. Has previously used CDPATH™ or PROSPECT results to assess CD risk for complications.

Studie plan

Dit gedeelte bevat details van het studieplan, inclusief hoe de studie is opgezet en wat de studie meet.

Hoe is de studie opgezet?

Ontwerpdetails

  • Primair doel: Diagnostisch
  • Toewijzing: NVT
  • Interventioneel model: Opdracht voor een enkele groep
  • Masker: Geen (open label)

Wapens en interventies

Deelnemersgroep / Arm
Interventie / Behandeling
Experimenteel: CDPATH™

Participants with CD will be using CDPATH™ tool. Clinical data will be collected via an ongoing registry. Participants and health care provider (HCP)-reported outcomes data will be collected periodically once every 6 months for up to 36 months via electronic surveys. Two baseline blood samples will be collected at screening for CDPATH™ analysis. 1 additional sample will be collected for future potential biomarker analysis.

Crohn's disease risk prediction tool.

Andere namen:
  • VERWACHTING

Three blood samples will be drawn.

Wat meet het onderzoek?

Primaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants in Real-world Practice in Each Risk Category at Baseline Based on the CDPATH™ Tool Results
Tijdsspanne: Baseline (Day 1)

The risk profile of an individual participant with CD is the output of the CDPATH™ tool. Categories for CD includes low, medium, high risk of developing a CD complication within 3 years.

Baseline (Day 1)

Secundaire uitkomstmaten

Uitkomstmaat
Maatregel Beschrijving
Tijdsspanne
Percentage of Participants with Specific Treatment Path and Choice Based on CDPATH™ Tool, Stratified According to Risk Category
Tijdsspanne: Up to 36 months

Treatment path (i.e., sequence over time) and choice, by low, medium and high risk, will be chosen to characterize treatment path and choice based on risk stratification.

Up to 36 months
Change From Baseline in Decisional Conflict Scale (DCS) Score
Tijdsspanne: Baseline, then every 6 months up to 36 months

DCS is a validated electronic patient-reported outcome (ePRO) collected via electronically administered patient surveys. It measures personal perceptions of the following responses: uncertainty in choosing options, modifiable factors contributing to uncertainty such as feeling uninformed, unclear about personal values and unsupported in decision making, and effective decision making such as feeling the choice is informed, values-based, likely to be implemented and expressing satisfaction with the choice. DCS involves answering 11 questions of PRO, of which 10 questions can be answered as yes (score = 0) or unsure (score = 2) or no (score =4). The total score will range from 0 to 40. Higher score indicates higher decisional conflict.

Baseline, then every 6 months up to 36 months
Change From Baseline in Work Productivity and Activity Impairment Questionnaire - CD Version (WPAI-CD) Score
Tijdsspanne: Baseline, then every 6 months up to 36 months

WPAI-CD is a validated ePRO collected via electronically administered patient surveys. It consists of six questions that evaluate 4 domain scores: absenteeism (i.e., work time missed), presenteeism (i.e., reduced work productivity), overall work impairment, and activity impairment. Scores are expressed as a percentage of impairment, where higher scores indicate greater impairment and reduced productivity. The total score ranges from 0 (no impairment) to 100% (total loss of work productivity).

Baseline, then every 6 months up to 36 months
Change From Baseline in Patient-Reported Outcomes Measurement Information System (PROMIS) Global Health Scale Score
Tijdsspanne: Baseline, then every 6 months up to 36 months

PROMIS Global Health scale is a validated ePRO collected via electronically administered patient surveys. It is a 10-item PRO measuring the overall evaluation of one's physical and mental health. The total score ranges from 0 to 100. The final score will be represented by the T-score metric, in which 50 is the mean of a relevant reference population and 10 is the standard deviation (SD) of that population. A higher PROMIS T-score represents more of the concept being measured (higher Global Health score indicate better health).

Baseline, then every 6 months up to 36 months
Patient-Reported Satisfaction and Experience Score with the CDPATH™ Tool
Tijdsspanne: Up to 36 months

Participant's satisfaction and experience with the CDPATH™ tool will be assessed based on 15 questions. Negative responses/lower score to/in these questions indicates less satisfaction whereas positive responses/higher score indicates satisfaction with the tool.

Up to 36 months
Number of Participants with Clinical Outcomes
Tijdsspanne: Up to 36 months

Participants with clinical outcomes describing the disease burden based on treatment path and controlling for risk strata will be reported.

Up to 36 months
Percentage of Participants with Healthcare Resource Utilization
Tijdsspanne: Up to 36 months

Healthcare resource includes healthcare provider (HCP) visits/referrals, visit to emergency room, hospitalizations, surgery, new CD-related complications, and diagnostic evaluations (e.g., imaging, colonoscopy, etc.).

Up to 36 months
Change from First Assessment in Health Care Provider (HCP)-reported Assessment of the Feasibility and Usability of the CDPATH™ Tool
Tijdsspanne: First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

HCP-reported CDPATH™ satisfaction data will be collected directly from HCPs via electronically administered HCP surveys and entered into the eCRF. HCPs will be queried regarding their satisfaction and experience with the general process, the ease of incorporating the tool in their everyday practice, and the impact of the tool on their treatment recommendations and participant communications. For the 6 questions, HCP will rate on 1-5 scale where, 1=strongly disagree and 5=strongly agree. For remaining 4 questions, written feedback from HCP will be consider. Overall positive responses will indicate higher feasibility and usability.

First assessment (6 months after HCPs first enrolled participant) up to HCP leaves the study or the study ends (up to 36 months)

Medewerkers en onderzoekers

Hier vindt u mensen en organisaties die betrokken zijn bij dit onderzoek.

Sponsor

Onderzoekers

  • Studie directeur: Study Director, Takeda

Publicaties en nuttige links

De persoon die verantwoordelijk is voor het invoeren van informatie over het onderzoek stelt deze publicaties vrijwillig ter beschikking. Dit kan gaan over alles wat met het onderzoek te maken heeft.

Studie record data

Deze datums volgen de voortgang van het onderzoeksdossier en de samenvatting van de ingediende resultaten bij ClinicalTrials.gov. Studieverslagen en gerapporteerde resultaten worden beoordeeld door de National Library of Medicine (NLM) om er zeker van te zijn dat ze voldoen aan specifieke kwaliteitscontrolenormen voordat ze op de openbare website worden geplaatst.

Bestudeer belangrijke data

Studie start (Werkelijk)

25 juni 2021

Primaire voltooiing (Werkelijk)

27 augustus 2026

Studie voltooiing (Werkelijk)

27 augustus 2026

Studieregistratiedata

Eerst ingediend

19 maart 2021

Eerst ingediend dat voldeed aan de QC-criteria

19 maart 2021

Eerst geplaatst (Werkelijk)

22 maart 2021

Updates van studierecords

Laatste update geplaatst (Werkelijk)

8 oktober 2026

Laatste update ingediend die voldeed aan QC-criteria

5 oktober 2026

Laatst geverifieerd

1 oktober 2026

Meer informatie

Termen gerelateerd aan deze studie

Plan Individuele Deelnemersgegevens (IPD)

Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?

JA

Beschrijving IPD-plan

Takeda provides access to the de-identified individual participant data (IPD) for eligible studies to aid qualified researchers in addressing legitimate scientific objectives (Takeda's data sharing commitment is available on https://clinicaltrials.takeda.com/takedas-commitment?commitment=5). These IPDs will be provided in a secure research environment following approval of a data sharing request, and under the terms of a data sharing agreement.

IPD-toegangscriteria voor delen

IPD from eligible studies will be shared with qualified researchers according to the criteria and process described on https://vivli.org/ourmember/takeda/. For approved requests, the researchers will be provided access to anonymized data (to respect patient privacy in line with applicable laws and regulations) and with information necessary to address the research objectives under the terms of a data sharing agreement.

IPD delen Ondersteunend informatietype

  • LEERPROTOCOOL
  • SAP
  • ICF
  • MVO

Informatie over medicijnen en apparaten, studiedocumenten

Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel

Nee

Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct

Nee

Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .

Abonneren